TWI346105B - Crystalline polymorph of bazedoxifene acetate - Google Patents

Crystalline polymorph of bazedoxifene acetate

Info

Publication number
TWI346105B
TWI346105B TW094110850A TW94110850A TWI346105B TW I346105 B TWI346105 B TW I346105B TW 094110850 A TW094110850 A TW 094110850A TW 94110850 A TW94110850 A TW 94110850A TW I346105 B TWI346105 B TW I346105B
Authority
TW
Taiwan
Prior art keywords
crystalline polymorph
bazedoxifene acetate
bazedoxifene
acetate
polymorph
Prior art date
Application number
TW094110850A
Other languages
English (en)
Chinese (zh)
Other versions
TW200606149A (en
Inventor
Christopher Demerson
Silvio Iera
Kadum Ali
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI346105(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200606149A publication Critical patent/TW200606149A/zh
Application granted granted Critical
Publication of TWI346105B publication Critical patent/TWI346105B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW094110850A 2004-04-07 2005-04-06 Crystalline polymorph of bazedoxifene acetate TWI346105B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56058204P 2004-04-07 2004-04-07
US66017805P 2005-03-10 2005-03-10

Publications (2)

Publication Number Publication Date
TW200606149A TW200606149A (en) 2006-02-16
TWI346105B true TWI346105B (en) 2011-08-01

Family

ID=34966308

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094110850A TWI346105B (en) 2004-04-07 2005-04-06 Crystalline polymorph of bazedoxifene acetate

Country Status (18)

Country Link
US (1) US7683051B2 (enExample)
EP (1) EP1732890A1 (enExample)
JP (2) JP2007532560A (enExample)
KR (1) KR20060135866A (enExample)
AR (1) AR048527A1 (enExample)
AU (1) AU2005233133A1 (enExample)
BR (1) BRPI0509191A (enExample)
CA (1) CA2561010A1 (enExample)
CR (1) CR8615A (enExample)
EC (1) ECSP066911A (enExample)
IL (1) IL178236A0 (enExample)
NO (1) NO20065052L (enExample)
PA (1) PA8629101A1 (enExample)
PE (1) PE20060676A1 (enExample)
RU (1) RU2006132180A (enExample)
SG (1) SG151331A1 (enExample)
TW (1) TWI346105B (enExample)
WO (1) WO2005100316A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005233133A1 (en) 2004-04-07 2005-10-27 Wyeth Crystalline polymorph of a bazedoxifene acetate
RU2006132352A (ru) 2004-04-07 2008-05-20 Вайет (Us) Кристаллическая полиморфная форма базедоксифен ацетата
US10645562B2 (en) 2004-09-21 2020-05-05 Agis Software Development Llc Method to provide ad hoc and password protected digital and voice networks
US8538393B1 (en) 2004-09-21 2013-09-17 Advanced Ground Information Systems, Inc. Method to provide ad hoc and password protected digital and voice networks
BRPI0612586A2 (pt) * 2005-06-29 2010-11-23 Wyeth Corp formulações de estrogênios conjugados e bazedoxifeno
JP2009506053A (ja) 2005-08-24 2009-02-12 ワイス 酢酸バゼドキシフェン製剤
PE20090100A1 (es) * 2007-03-30 2009-02-26 Wyeth Corp Metodos de separacion y deteccion de acetato de bacedoxifeno en composiciones farmaceuticas
CZ302358B6 (cs) * 2007-07-25 2011-03-30 Zentiva, A. S. Nové soli bazedoxifenu
WO2009102771A1 (en) * 2008-02-11 2009-08-20 Wyeth Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate
CA2714494A1 (en) 2008-02-11 2009-08-20 Wyeth Llc Methods of preparing polymorphic form a of bazedoxifene acetate
WO2009102778A1 (en) * 2008-02-11 2009-08-20 Wyeth Amorphous polymorph of bazedoxifene acetate
ITMI20091109A1 (it) * 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
WO2011056532A2 (en) 2009-10-27 2011-05-12 Wyeth Llc Bazedoxifene formulations with antioxidants
US8154175B2 (en) * 2009-12-16 2012-04-10 Hamilton Sundstrand Corporation Sensing device
WO2012007453A1 (en) 2010-07-14 2012-01-19 Sandoz Ag Crystalline compound of 1-[4-(2-azepan-1-ylethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
WO2012037187A2 (en) * 2010-09-14 2012-03-22 Dr. Reddy's Laboratories Ltd. Preparation of crystalline bazedoxifene and its salts
EP2471770A1 (en) 2010-12-28 2012-07-04 Sandoz Ag Method of preparing polymorphic pure form A of bazedoxifene acetate
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
JP2016518449A (ja) 2013-05-15 2016-06-23 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インドール製剤を調製するためのプロセスおよび中間体
CN111060619B (zh) * 2019-12-18 2022-11-18 北京鑫开元医药科技有限公司 一种醋酸巴多昔芬杂质的检测方法
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
ES2162198T3 (es) 1996-04-19 2001-12-16 American Home Prod Agentes estrogenos.
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
ATE355264T1 (de) * 1997-10-15 2006-03-15 Wyeth Corp Neue aryloxy-alkyl-dialkylamine
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
CA2489813A1 (en) 2002-06-25 2003-12-31 Wyeth Use of thio-oxindole derivatives in treatment of hormone-related conditions
AU2005233133A1 (en) 2004-04-07 2005-10-27 Wyeth Crystalline polymorph of a bazedoxifene acetate

Also Published As

Publication number Publication date
IL178236A0 (en) 2006-12-31
CR8615A (es) 2007-06-06
ECSP066911A (es) 2006-12-20
EP1732890A1 (en) 2006-12-20
RU2006132180A (ru) 2008-05-20
PE20060676A1 (es) 2006-07-24
SG151331A1 (en) 2009-04-30
NO20065052L (no) 2006-11-06
WO2005100316A1 (en) 2005-10-27
TW200606149A (en) 2006-02-16
US7683051B2 (en) 2010-03-23
PA8629101A1 (es) 2005-11-25
KR20060135866A (ko) 2006-12-29
AR048527A1 (es) 2006-05-03
CA2561010A1 (en) 2005-10-27
BRPI0509191A (pt) 2007-09-25
AU2005233133A1 (en) 2005-10-27
US20050227965A1 (en) 2005-10-13
JP2009035535A (ja) 2009-02-19
JP2007532560A (ja) 2007-11-15

Similar Documents

Publication Publication Date Title
TWI346105B (en) Crystalline polymorph of bazedoxifene acetate
ZA200608361B (en) Crystalline polymorph of bazedoxifene acetate
PT1802579E (pt) Derivados da 3-arilaminopiridina
IL180358A0 (en) Crystalline form iv of linezolid
IL196706A0 (en) Crystalline forms of rapamycin analogs
IL233392A (en) Compositions of bazodoxifene acetate
IL198262A0 (en) Crystalline modification of fipronil
IL198266A0 (en) Crystalline modification of fipronil
ZA200903967B (en) Crystalline modification of fipronil
IL183380A0 (en) Crystalline forms of linezolid intermediate
IL193399A0 (en) Novel crystalline forms of armodafinil and preparation thereof
IL198265A (en) Crystalline change of fibronyl
IL181597A0 (en) Process for isolation of crystalline tacrolimus
IL177762A0 (en) Bimatoprost crystalline form i
EP1804582A4 (en) POLYMORPH SHAPES OF TADALAFIL
EP1773339A4 (en) CRYSTALLINE FORM OF DONEPEZIL HYDROCHLORIDE
IL195061A0 (en) Crystalline forms of atorvastatin
GB0509720D0 (en) Configuration of VPNs
ZA200806859B (en) Novel crystalline compounds
IL177711A0 (en) Crystalline pyrazole derivative
HK1098749A (en) Crystalline polymorph of bazedoxifene acetate
SI1812422T1 (sl) Kristalna oblika irbesartana
EP1878719A4 (en) HYDROXYNOREPHEDRINE DERIVATIVE HYDROCHLORIDE POLYMORPH CRYSTAL
HK1094802A (en) Crystalline polymorph of a bazedoxifene acetate
IL195092A0 (en) Crystalline form of (s)-1-phenylethylammonium (r)-diphenyl-methanesulphinyl-acetate

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent